Informazioni sul prodotto
- 4-[[2-Fluoro-3-[[[(6-methyl-3-pyridinyl-d8)amino]carbonyl]amino]phenyl]methyl]-1-piperazinecarboxylic Acid Methyl Ester
- Omecamtiv Mecarbil
- Methyl 4-[[2-Fluoro-3-[N'-(6-methylpyridin-3-yl-d8)ureido]phenyl]methyl]piperazine-1-carboxylate
- 4-[[2-Fluoro-3-[[[(6-methyl-3-pyridinyl-d8)amino]carbonyl]amino]phenyl]methyl]-1-piperazinecarboxylic Acid Methyl Ester
- Ck-1827452
- Methyl 4-[[2-fluoro-3-[N′-(6-methylpyridin-3-yl)ureido]phenyl]methyl]piperazine-1-carboxylate
- Omecamtiv mecarbil
- 1-Piperazinecarboxylic acid, 4-[[2-fluoro-3-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenyl]methyl]-, methyl ester
Applications CK 1827452-d8 is the labeled analogue of CK 1827452 (C544000), a promising new drug in systolic heart failure. It accelerates the transition of myosin into the force-generating state without affecting cardiac myocyte calcium homeostasis. CK 1827452 increases cardiac function by increasing the duration of ejection without changing the rates of contraction.
References Meijs, M. et al.: Eur. J. Heart. Fail., 14, 232 (2012); Malik, F. et al.: J. Mol. Cell. Card., 51, 454 (2011)
Proprietà chimiche
Richiesta tecnica su: TR-C544002 CK 1827452-d8
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.